Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPS-MS
NCT01591551Phase 4Completed
- Sponsor
- Cornerstone Health Care
- Start
- Mar 2012
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of natalizumab in multiple sclerosis (MS), sponsored by Cornerstone Health Care. Primary endpoints: Sleep Efficiency at 6 months, Total Sleep Time at 6 months and 1 more. Started Mar 2012; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT01591551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01591551.